ALD 201

Drug Profile

ALD 201

Alternative Names: ALD-201

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Aldagen
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 05 May 2014 Discontinued - Phase-I for Ischaemic heart disorders in USA (Intracoronary)
  • 07 May 2012 ALD 201 is available for licensing as of 29 Mar 2012. http://www.cytomedix.com
  • 15 Mar 2012 Efficacy and adverse events data from a phase I trial in Ischaemic heart disorders released by Cytomedix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top